BRANDY CAIN: Open Payments
NPI 1104332543 · CHATTANOOGA, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 25 payments from 11 companies in 2025. Trend: 2023 $499 · 2024 $546 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $192 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $60 |
| Lilly USA, LLC | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
| Novo Nordisk Inc | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Abbott Laboratories | 1 | $15 |
| Amgen Inc. | 1 | $14 |
Products named: VRAYLAR, JARDIANCE, CAPLYTA, Auvelity, QULIPTA, XIFAXAN, Ozempic, GEMTESA.
Industry payments across TN — which companies pay providers there.
